Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Trial Details

NCT ID

NCT06521255

Phase

PHASE3

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Tafasitamab
• Lenalidomide
• Gemcitabine
• Oxaliplatin
• Rituximab

Locations (sample)

• Beijing, China|39.9075,116.39723
• Changchun, China|43.88,125.32278
• Changsha, China|28.19874,112.97087
• Chaozhou, China|23.65396,116.62262
• Chengdu, China|30.66667,104.06667

Key Eligibility Criteria

• 18 Years and older.
• One of the histologies of DLBCL confirmed by participated sites below with，not otherwise specified;T-cell/histiocyte-rich large B-cell lymphoma;Eps…
• Availability of tumor tissue biopsied post last line of therapy and prior to current study treatment for the patients enrolled in safety and tolera…
• Relapsed/refractory (R/R) DLBCL, at least one (≥1) but no more than three (≤3) line of prior systemic therapies.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.